1'757 companies found
Pharmotech SA
Eysins · Since 2018
The core activity of Pharmotech SA is the research and development of medical products based on plant-based active ingredients, particularly CBD, to combat multi-resistant bacteria (MDR-MRSA). The company focuses on researching and developing innovative solutions to combat bacteria such as Pseudomonas Aeruginosa and Staphylococcus Aureus.
Pharmunion SA
Zurich · Since 1969
The core activity of Pharmunion SA is the development, manufacture and analysis of pharmaceutical products, as well as the provision of laboratory services for B2B customers and private individuals. This includes in particular: the manufacture of pharmaceutical, chemical, biological, dietary, cosmetic and similar products; the performance of laboratory analyses and tests for pharmaceutical products; the development of innovative medicines based on research and development; and the provision of laboratory services for B2B customers and private individuals. The company is based in Switzerland and has its own certified laboratory facility.
Phialogics AG
Allschwil · Since 2022
Probiotical Swiss SA
Lugano · Since 2013
PTC Therapeutics Switzerland GmbH
Steinhausen · Since 2014
The company's core activity is the development, manufacture and marketing of medicines for rare diseases. The company focuses on the discovery, development and global marketing of clinically differentiated medicines for patients with rare diseases.
Red Ridge Bio AG
Basel · Since 2021
RegulaNova Sàrl
Geneva · Since 2020
Release Therapeutics SA
Geneva · Since 2005
The core activity of Relief Therapeutics is the development and marketing of new, patented therapeutics for rare and ultra-rare diseases, particularly for patients with severe illnesses for which there are currently no or only limited treatment options. The company focuses on developing medications for specific diseases such as Epidermolysis Bullosa, Phenylketonuria and other rare conditions.
ReMedys Foundation
Geneva · Since 2013
The core activity of ReMedys is to develop and promote innovative therapeutic approaches for patients with severe diseases without effective treatment, regardless of their commercial potential. To this end, ReMedys works in partnership with academic research institutions and industry experts to translate research results into clinical trials and develops new medicines in a project-based approach.
Rigi Therapeutics AG
Meggen · Since 2023
Roche Chemical Manufacturing and Trading Company AG
Basel · Since 2024
Roche Holding AG
Basel · Since 1966
ROELMI HPC SWISS SA
Viganello · Since 2008
Sanuman AG
Birsfelden · Since 1984
Scintec Diagnostics GmbH
Baar · Since 1997
Shield TX (Switzerland) AG
Wollerau · Since 2009
The core activity of Shield Therapeutics plc is the development and marketing of specialized pharmaceuticals, particularly for the treatment of iron deficiency, including anemia. The company focuses on developing medications that improve the lives of people with iron deficiency and has already developed a leading product called ACCRUFeR®, which is approved for the treatment of iron deficiency in adults.
Sigma-Aldrich International GmbH
Buchs Sg · Since 1999
SOLID Drug Development SA
Geneva · Since 2010
The core activity of Solid Drug Development is strategic and operational consulting for the development of biotech and pharmaceutical products. Specifically, the company supports the development of medicines from the laboratory phase to clinical testing and helps reduce costs and operational problems for pharmaceutical companies.
S.P. Laboratories SA
Pully · Since 2003
The core activity of SP Laboratory is the development, manufacture and distribution of pharmaceutical products, particularly medicines produced under special formulations and strict quality controls. The company also offers services such as contract manufacturing of medicines for pharmaceutical companies and supports them in obtaining the necessary legal authorizations.
SpringWorks Therapeutics Europe GmbH
Zug · Since 2024
The company is a biotechnology company specializing in the development of drugs for the treatment of cancer, particularly rare cancer types such as Multiple Myeloma, Desmoid tumors and NF1-PN.
Outbound Leads by COHAGALeadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Discover LeadhubHow the search works, what each filter means, and how the results come together.
Source: Federal Statistical Office, UID register